Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Net Income for the year ending December 31, 2023: USD -47.70 M

Nyxoah S.A. Net Income is USD -47.70 M for the year ending December 31, 2023, a -42.76% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Nyxoah S.A. Net Income for the year ending December 31, 2022 was USD -33.41 M, a -6.26% change year over year.
Nyxoah S.A. Net Income for the year ending December 31, 2021 was USD -31.44 M, a -110.19% change year over year.
Nyxoah S.A. Net Income for the year ending December 31, 2020 was USD -14.96 M, a -83.72% change year over year.
Nyxoah S.A. Net Income for the year ending December 31, 2019 was USD -8.14 M, a 21.64% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years